{"id":"NCT00383240","sponsor":"Organon and Co","briefTitle":"Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04334AM1)(COMPLETED)","officialTitle":"A 26-Week Placebo-Controlled Efficacy and Safety Study of Mometasone Furoate/Formoterol Fumarate Combination Formulation Compared With Mometasone Furoate and Formoterol Monotherapy in Subjects With Persistent Asthma Previously Treated With Medium-Dose Inhaled Glucocorticosteroids","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-09","primaryCompletion":"2008-09","completion":"2008-09","firstPosted":"2006-10-03","resultsPosted":"2011-03-07","lastUpdate":"2024-05-20"},"enrollment":781,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"DRUG","name":"mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID","otherNames":["SCH 418131"]},{"type":"DRUG","name":"Mometasone furoate MDI (MF MDI) 200 mcg","otherNames":["SCH 32088"]},{"type":"DRUG","name":"formoterol fumarate 10 mcg","otherNames":["Foradil"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"MF/F MDI 200/10 mcg BID","type":"EXPERIMENTAL"},{"label":"MF MDI 200 mcg BID","type":"EXPERIMENTAL"},{"label":"F MDI 10 mcg BID","type":"EXPERIMENTAL"},{"label":"Placebo BID","type":"PLACEBO_COMPARATOR"}],"summary":"This is a randomized, multi-center, double-blind, double-dummy, placebo-controlled, parallel-group study, evaluating the efficacy of mometasone furoate (MF) /formoterol fumarate (F)\\[MF/F\\] metered dose inhaler (MDI) versus MF for 26 weeks. Prior to the 26-week double-blind Treatment Period, subjects will receive open-label MF MDI 200 mcg twice daily (BID) for 2 to 3 weeks during the Run-in Period. Efficacy will be measured by The Area Under the Curve From 0 to 12 Hours \\[AUC\\](0-12 hours) of the Change From Baseline to the Week 12 Endpoint\n\nin Forced Expiratory Volume in One Second (FEV1) \\[Time Frame: Baseline to Week 12\\] and Time-to-First Severe Asthma Exacerbation across the 26-week treatment period.","primaryOutcome":{"measure":"Mean Area Under the Time Curve From 0 to 12 Hours (AUC(0-12 Hours)) of Change From Baseline to Week 12 in Forced Expiratory Volume (Liters) in 1 Second (FEV1) for MF/F Versus MF","timeFrame":"Baseline to Endpoint (12 weeks)","effectByArm":[{"arm":"MF/F MDI 200/10 mcg BID","deltaMin":3.2,"sd":2.96},{"arm":"MF MDI 200 mcg BID","deltaMin":1.29,"sd":2.96},{"arm":"F MDI 10 mcg BID","deltaMin":2.73,"sd":2.96},{"arm":"Placebo BID","deltaMin":1.42,"sd":2.96}],"pValues":[{"comp":"OG000 vs OG001","p":"<.001"},{"comp":"OG000 vs OG002","p":"<.001"},{"comp":"OG000 vs OG003","p":"<.001"},{"comp":"OG001 vs OG002","p":"0.491"},{"comp":"OG001 vs OG003","p":"0.055"},{"comp":"OG002 vs OG003","p":"0.008"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":13},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["20678306"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":984},"commonTop":["UPPER RESPIRATORY TRACT INFECTION","NASOPHARYNGITIS","HEADACHE"]}}